Here are the DEF 14A proxy statements from VSee Health Inc WTS 29 (VSEEW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow VSEEW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VSEEW filings page.
VSee Health, Inc. is asking stockholders to vote at a virtual annual meeting on August 25, 2026 on four items: electing two Class II directors to terms ending in 2029, ratifying WWC, P.C. as auditor for 2026, authorizing a reverse stock split, and permitting meeting adjournments if more time is needed to solicit votes.
The board seeks authority to implement one or more reverse stock splits of the common stock at ratios from 1-for-20 up to an aggregate 1-for-80 within two years of the July 6, 2026 record date, mainly to support Nasdaq listing compliance and broaden institutional interest, while warning of possible reduced liquidity, dilution from future issuances, and no assurance of sustained price improvement.
As of the record date there were 55,679,813 common shares and 121.6980 preferred shares outstanding, together entitled to 55,692,0‑plus votes, with quorum set at one-third of voting power. The proxy details a classified, majority-independent board, committee structure, significant related-party financing and debt-to-equity conversions, and discloses that the company currently lacks formalized cybersecurity measures but plans to develop a board‑overseen framework.
VSee Health, Inc. has called a virtual special meeting on March 2, 2026 to ask stockholders to approve a prior private placement under Nasdaq Listing Rule 5635(d). The company sold 9,836,065 shares of common stock (or pre-funded warrants) plus warrants for up to 19,672,130 shares in a November 2025 private offering, raising approximately $6 million at $0.61 per share.
Stockholders are being asked to approve the potential issuance of the warrant shares, which would exceed 20% of currently outstanding common stock, and to authorize possible adjournment of the meeting if more time is needed to gather votes. Common and Series A Preferred holders of record on February 2, 2026 are entitled to vote.